• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by TNF Pharmaceuticals Inc.

    8/14/25 5:01:51 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $TNFA alert in real time by email
    NT 10-Q 1 formnt10-q.htm NT 10-Q

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

     

      For Period Ended: June 30, 2025

     

      ☐ Transition Report on Form 10-K
      ☐ Transition Report on Form 20-F
      ☐ Transition Report on Form 11-K
      ☐ Transition Report on Form 10-Q

     

      For the Transition Period Ended:
      ___________________________________

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I – REGISTRANT INFORMATION

     

    TNF Pharmaceuticals, Inc.

    Full Name of Registrant

     

    N/A

    Former Name if Applicable

     

    1185 Avenue of the Americas. Suite 249

    Address of Principal Executive Office (Street and Number)

     

    New York, NY 10036

    City, State and Zip Code

     

     

     

     

     

     

    PART II – RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

       (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
    ☒  (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
       (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III – NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    TNF Pharmaceuticals, Inc. (the “Company”) is unable to file, without unreasonable effort and expense, its Quarterly Report on Form 10-Q for the six months ended June 30, 2025 (the “Form 10-Q”), because the Company requires additional time to complete and finalize its financial statements required to be included in the Form 10-Q. The Company currently anticipates that the Form 10-Q will be filed on or before the fifth calendar day following the prescribed due date. 

     

    PART IV – OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    Joshua Silverman   856   848-8698
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐
       
       
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
      Yes ☐ No ☒
       

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    2

     

     

    TNF Pharmaceuticals, Inc.

    (Name of registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: August 14, 2025   By: /s/ Joshua Silverman
          Name: Joshua Silverman
          Title: Director

     

    3

    Get the next $TNFA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNFA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TNFA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Vice President, Finance Rauch Gary M

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:15 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by President, CMO Glass Mitchell

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:12 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Interim CFO Rhodes Ian

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:14 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    SEC Filings

    View All

    TNF Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    9/26/25 5:10:36 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    9/10/25 5:00:34 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: TNF Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    9/5/25 5:30:47 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"

    Licensed technology positions Company at forefront of new quantum-class computing paradigm Q/C Technologies, Inc. (NASDAQ:QCLS), formerly TNF Pharmaceuticals, Inc. (NASDAQ: TNFA), ("Q/C" or "the Company"), today announced that its common stock will begin trading under the new ticker symbol "QCLS" beginning today at the market open. The Company's new name Q/C Technologies represents its recent strategic pivot into quantum-class computing with exclusive global rights to LightSolver's light-speed laser processing unit (LPU), the world's first light and laser-based computing system, for application in quantum class cryptocurrency verticals. "The official transition to Q/C Technologies and

    9/25/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic Computing

    New trading symbol QCLS effective Thursday, September 25, 2025 Licensed technology positions Company at forefront of new quantum-class computing paradigm TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("Q/C" or the "Company") today announced that it has changed its corporate name to Q/C Technologies, Inc. and will begin trading under the new ticker symbol "QCLS" on the Nasdaq Capital Market, effective as of the market open on Thursday, September 25, 2025. Until then, the Company's common stock will continue to trade under its current ticker symbol "TNFA." The new name Q/C Technologies represents the Company's recent strategic pivot into quantum-class computing with exclusive global rights to

    9/24/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

    TNF Pharmaceuticals Inc. (NASDAQ:TNFA), ("TNF" or the "Company") today announced that it received written notice from the Nasdaq Stock Market on September 16, 2025, confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2). To regain compliance with the Listing Rule, the Company's shares maintained the minimum bid price of $1.00 for 10 consecutive business days. "We are pleased to have regained compliance with Nasdaq's listing standards. This milestone comes as we work to build a strong strategic platform for growth and shareholder value. We will be updating shareholders on our progress in the weeks ahead,"

    9/17/25 9:24:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    Financials

    Live finance-specific insights

    View All

    TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

    Concurrent clinical studies underway evaluating novel TNF-alpha inhibitor for treating muscle loss associated with hip/femur fracture repair, GLP-1 weight loss Investors invited to submit questions prior to the event TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it will host an investor conference call and webcast on Thursday, March 6, 2025, at 4:30 pm ET. Mitchell Glass, M.D., President and Chief Medical Officer of TNF, will provide a clinical scientific update on the Company's lead candidate isomyosamine, a novel oral TNF

    3/5/25 9:00:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TNF Pharmaceuticals Inc.

    SC 13G/A - TNF Pharmaceuticals, Inc. (0001321834) (Subject)

    11/14/24 2:24:58 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care